Sarcoma
Conditions
Keywords
adult liposarcoma, recurrent adult soft tissue sarcoma
Brief summary
RATIONALE: Rosiglitazone may help liposarcoma cells develop into normal fat cells. PURPOSE: Phase II trial to study the effectiveness of rosiglitazone in treating patients who have liposarcoma.
Detailed description
OBJECTIVES: * Determine the clinical activity of rosiglitazone in patients with liposarcoma. * Assess the impact of this regimen on markers of tumor proliferation and differentiation status in these patients using biologic and biochemical testing and correlative imaging. * Determine the tolerance and safety of this regimen in these patients. OUTLINE: Patients are stratified by histologic subtype (well differentiated vs dedifferentiated vs myxoid/round cell vs pleomorphic). Patients receive oral rosiglitazone twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed at 1-3 weeks and then every 3 months thereafter. PROJECTED ACCRUAL: A total of 56-120 patients (14-30 per stratum) will be accrued for this study within 15 months.
Interventions
Sponsors
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically proven liposarcoma that is incurable with standard multimodality approaches (e.g., surgery and/or radiotherapy and/or chemotherapy) * Well differentiated OR * Dedifferentiated OR * Myxoid/round cell OR * Pleomorphic * Measurable disease * No clinically unstable brain metastases * No progression on prior troglitazone therapy for liposarcoma PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-2 Life expectancy: * At least 3 months Hematopoietic: * Absolute neutrophil count at least 1,000/mm3 * Platelet count at least 90,000/mm3 Hepatic: * Bilirubin no greater than 2.0 mg/dL * SGOT less than 5 times upper limit of normal Renal: * Creatinine no greater than 2.4 mg/dL Cardiovascular: * No poorly controlled atrial arrhythmias, symptomatic angina pectoris, or myocardial infarction within the past 4 months * No symptomatic congestive heart failure, percutaneous transluminal coronary angioplasty, or coronary artery bypass graft within the past 3 months Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective barrier contraception * Oral contraceptives are not considered effective contraception * No active retroviral disease * No condition that would preclude informed consent PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * See Disease Characteristics * Prior chemotherapy allowed and recovered * No concurrent cytotoxic therapy Endocrine therapy: * No concurrent hormonal therapy Radiotherapy: * See Disease Characteristics * Prior radiotherapy allowed and recovered * At least 6 months since prior radiotherapy to the sole site of measurable disease * Concurrent localized radiotherapy to a single site of disease allowed if there are other sites of measurable disease Surgery: * Not specified
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evidence of biological response | — | Evidence of biological response can be measured or defined by intracytoplasmic microvesicular lipid accumulation, consistent with adipocytic differentiation in liposarcoma cells. Biological response can also be measured by clinically stable disease for x\>3 months, as well as standard clinical trial criteria for objective clinical response. Complete response is defined by total resolution of all detectable disease lasting for at least four weeks. Partial remission is a decrease of over 50% in the sum of the products of the largest perpendicular diameters of all measurable lesions, persisting for at least four weeks, without progression of any non-measurable sites, and without appearance of any new sites of disease. |
Countries
United States
Outcome results
None listed